|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A critical survey of technologies of large offshore wind farm integration: summary, advances, and perspectives显示文摘Offshore wind farms(OWFs)have received widespread attention for their abundant unexploited wind energy poten-tial and convenient locations conditions.They are rapidly developing towards having large capacity and being located further away from shore.It is thus necessary to explore effective power transmission technologies to connect large OWFs to onshore grids.At present,three types of power transmission technologies have been proposed for large OWF integration.They are:high voltage alternating current(HVAC)transmission,high voltage direct current(HVDC)transmission,and low-frequency alternating current(LFAC)or fractional frequency alternating current transmission.This work undertakes a comprehensive review of grid connection technologies for large OWF integration.Compared with previous reviews,a more exhaustive summary is provided to elaborate HVAC,LFAC,and five HVDC topologies,consisting of line-commutated converter HVDC,voltage source converter HVDC,hybrid-HVDC,diode rectifier-based HVDC,and all DC transmission systems.The fault ride-through technologies of the grid connection schemes are also presented in detail to provide research references and guidelines for researchers.In addition,a comprehensive evalu-ation of the seven grid connection technologies for large OWFs is proposed based on eight specific indicators.Finally,eight conclusions and six perspectives are outlined for future research in integrating large OWFs. | Bo Yang Bingqiang Liu Hongyu Zhou Jingbo Wang Wei Yao Shaocong Wu Hongchun Shu Yaxing Ren | 2022 | Protection and Control of Modern Power Systems2022，7，1： | 4 |
| 2 | A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block “eat-me” signal显示文摘Immune checkpoint inhibitors(ICIs)have induced durable clinical responses in a subset of patients with colorectal cancer(CRC).However,the dis-satisfactory response rate and the lack of appropriate biomarkers for selecting suitable patients to be treated with ICIs pose a major challenge to current immunotherapies.Inflammation-related molecule A20 is closely related to cancer immune response,but the effect of A20 on“eat-me”signal and immunotherapy efficacy remains elusive.We found that A20 downregulation prominently improved the antitumor immune response and the efficacy of PD-1 inhibitor in CRC in vitro and in vivo.Higher A20 expression was associated with less infiltration of immune cells including CD3(+),CD8(+)T cells and macrophages in CRC tissues and also poorer prognosis.Gain-and loss-A20 functional studies proved that A20 could decrease the“eat-me”signal calreticulin(CRT)protein on cell membrane translocation via upregulating stanniocalcin 1(STC1),binding to CRT and detaining in mitochondria.Mechanistically,A20 inhibited GSK3βphosphorylating STC1 at Thr86 to slow down the degradation of STC1 protein.Our findings reveal a new crosstalk between inflammatory molecule A20 and“eat-me”signal in CRC,which may represent a novel predictive biomarker for selecting CRC patients most likely to benefit from ICI therapy. | Min Luo Xueping Wang Shaocong Wu Chuan Yang Qiao Su Lamei Huang Kai Fu Sainan An Fachao Xie Kenneth Kin Wah To Fang Wang Liwu Fu | 2023 | Signal Transduction and Targeted Therapy2023，8，9： | 1 |
| 3 | PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma显示文摘ERK pathway regulated the programmed death ligand-1(PD-L1)expression which was linked to the response of programmed death-1(PD-1)/PD-L1 blockade therapy.So it is deducible that ERK inhibitor could enhance the efficacy of PD-1 inhibitor in cancer immunotherapy.In this study,PD0325901,an oral potent ERK inhibitor,strongly enhanced the efficacy of PD-1 antibody in vitro and in vivo models in non-small cell lung carcinoma(NSCLC)cells.Mechanistically,PD0325901 or shRNA-ERK1/2 significantly downregulated the PD-L1 expression in NSCLC cells and increased the CD3+T cells infiltration and functions in tumor tissue.There was a positive correlation between the p-ERK1/2 expression and PD-L1 expression in patients with NSCLC.And the patients with low p-ERK1/2 expression were observed a high response rate of PD-1/PD-L1 blockage therapy.Our results demonstrate that PD0325901,an ERK inhibitor,can enhance the efficacy of PD-1 blockage against NSCLC in vitro and in vivo models.And the combination of ERK inhibitor such as PD0325901 and PD-1/PD-L1 blockage is a promising regimen and encouraged to be further confirmed in the treatment of patients with NSCLC. | Min Luo Yuhui Xia Fang Wang Hong Zhang Danting Su Chaoyue Su Chuan Yang Shaocong Wu Sainan An Suxia Lin Liwu Fu | 2021 | Acta Pharmaceutica Sinica B2021，11，10： | 1 |
| 4 | Fiber Supercapacitors Utilizing Pen Ink for Flexible/Wearable Energy Storage显示文摘 | Yongping Fu Xin Cai Hongwei Wu Zhibin Lv Shaocong Hou Ming Peng Xiao Yu Dechun Zou | 2012 | Adv Mater2012，，42： | 1 |
| 5 | Dye‐Sensitized Solar Cells with Vertically Aligned TiO<sub>2</sub> Nanowire Arrays Grown on Carbon Fibers显示文摘 | Xin Cai Hongwei Wu Shaocong Hou Ming Peng Xiao Yu Dechun Zou | 2014 | ChemSusChem2014，，2： | 1 |
| 6 | Fiber Supercapacitors Utilizing Pen Ink for Flexible/Wearable Energy Storage显示文摘 | Yongping Fu Xin Cai Hongwei Wu Zhibin Lv Shaocong Hou Ming Peng Xiao Yu Dechun Zou | 2012 | Adv Mater2012，，42： | 1 |
| 7 | Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer显示文摘Programmed death ligand 1(PD-L1)immune checkpoint inhibitors are promising therapeutic agents for treating cancers but the response rate is<20%.Some chemotherapeutic drugs could also activate an anticancer immune response to kill cancer cells,apart from their direct cytotoxicity.Our study investigated the combination of chemotherapeutic drugs with PD-L1 antibody to enhance the response rate of PD-L1 blockade.Non-small cell lung cancer(NSCLC)cells were pre-treated with mitomycin C(MMC)and then co-cultured with peripheral blood mononuclear cells(PBMCs)to investigate the effect of the combination of MMC with PD-L1 antibody.The drug combination was also evaluated in vivo in Lewis lung cancer(LLC)cells-bearing C57BL/6 mice.MMC increased the expressions of PD-L1 and MHC-I in NSCLC cells in vitro and in vivo and enhanced the cytotoxic effect of lymphocytes on NSCLC in vitro.In LLC-bearing mouse model,the combination of MMC and PD-L1 antibody was found to be more effective in retarding tumor growth and prolonging overall survival than either single treatment alone,which was associated with increased lymphocyte infiltration and granzyme B release.Mechanistically,MMC activated the ERK pathway,which subsequently enhanced the binding of c-JUN to the PD-L1 promoter and recruited its co-factor STAT3 to increase PD-L1 expression.The upregulated ERK pathway was shown to activate p65 to increase the MHC-I expression.MMC was shown to enhance the efficacy of PD-L1 blockade in NSCLC cells.Further study is warranted to translate the findings to clinical application. | Min Luo Fang Wang Hong Zhang Kenneth KWTo Shaocong Wu Zhen Chen Shaobo Liang Liwu Fu | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员